美国医疗器械促进协会---AAMI（au/）
Profile
AAMI: Leading insurer. Pacetter in customer benefits and rvice.
AAMI is a leading car, home, compulsory third party (CTP) and small business insurer. We deal directly with our customers and we u innovative business and marketing strategies to provide them with high quality products and excellent customer rvice. You've already found we're easy to contact.
Insurance benefits such as no fault, no penalty; lifetime repair guarantee; lifetime rating one/maximum no claim bonus; valet rvice; progressive no claim discount on home insurance and the first general insurance customer charter were all introduced by AAMI.
Established in 1970, AAMI today has more than 2.5 million policyholders and millions of incoming telephone calls annually.
history
Incorporated in Victoria in September 1969, AAMI commenced business on 1 January 1970 as a motor vehicle insurer, offering a major independent alternative to government-owned and motor club-owned insurers. However, it was back in 1934, on 7 January, that the first policy was granted, but not by AAMI as it is known today. The risk was underwritten by a company called Club Motor Insurance Agency (Club Motor).
Club Motor was established in 1933 as a highly specialid company to provide motor vehicle insurance for members of the RACV in Victoria, the RACQ in Queensland and the RACT in Tasmania. The Club Motor arrangement continued until 31 December 1969, when the RACV decided to become an insurer in its own right. The RACQ quickly followed suit so that only the RACT remained in the fold. But what was the end of a long liaison, was the beginning for AAMI as it is known today. After the split, and to avoid customer confusion, Club Motor's consortium of shareholders, which read like the who's who of the insurance industry, was no longer able to u the Club Motor name, so they decided on the name Australian Associated Motor Insurers Limited, known as AAMI.
会计职业道德
In 1978, AAMI branched out into South Australia and then into New South Wales in 1983. The RACT broke away from AAMI in 1985. However AAMI was able to retain 80% of that business. In 1989 came AAMI's decision to diversify. After nearly 20 years of operating solely in car insurance, AAMI launched into the home insurance market. This move was the result of a detailed analysis of the benefits of applying AAMI's strengths, experience and infrastructure to other endeavours without diluting its motoring experti. The year 1989 also saw the deregulation of the CTP market in New South Wales, with AAMI being granted a licence to operate. In 1993, AAMI entered the Queensland CTP market.
一元函数微分学
小学生成语AAMI's business has continued to grow and develop so that, today, home insurance and CTP insurance are major components, making increasingly important contributions to the company's results.
乐高教育
女英文名大全WuXi AppTec 副总裁兼总经理受邀加入美国医疗仪器促进协会 (AAMI) 标准委员会
在中美两国均有运营实体，全球领先的医药、生物制药以及医疗器械研发外包服务企业
药明康德 (NYSE: WX)，今日荣幸宣布其位于美国的子公司之一 WuXi AppTec 亚特兰大运营分部的副总裁兼总经理 Trabue D. Bryans 女士受邀加入美国医疗仪器促进协会 (AAMI) 标准委员会，任期三年。
消防安全责任制 药明康德简介：
药明康德新药开发有限公司于2000年12月成立，妾室养儿记是全球领先的制药、生物技术以及医疗器械研发外包服务公司。作为一家以研究为首任，以客户为中心的公司，药明康德向全球制药公司、生物技术公司以及医疗器械公司提供一系列全方位的实验室研发，研究生产，生物制剂测试以及生产服务，服务范围贯穿制药和医疗器械研发全过程。药明康德的服务旨在帮助其全球合作伙伴缩短药物及医疗器械研发周期、降低研发成本。
服务分为两大部分： （1）实验室服务：包括从药物发现到开发的全方位制药服务，生物制品和医疗器械开发和测试服务，以及全面的毒理服务。 （2）生产服务：药物中间体、高效能原料药(APIs)的生产服务，细胞银行服务，细胞疗法和基于化合物和组织的产品的cGMP生产。
Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company with operations in China and the United States. As a rearch-driven and customer-focud company, WuXi AppTec provides a broad and integrated portfolio of laboratory and manufacturing rvices from discovery to commercialization. Our rvices are designed to help our worldwide customers shorten the time and lower the cost of drug and medical device R&D through cost-effective and efficient outsourcing solutions.
We group our operations into two gments:
∙Laboratory Services
A full range of discovery and development rvices for pharmaceuticals; development and testing rvices for biotherapeutics and medical devices; and comprehensive toxicology rvices.
∙Manufacturing Services
Manufacturing rvices for advanced intermediates and active pharmaceutical ingredient
s (APIs); cell banking rvices; and cGMP manufacturing for cellular therapeutics and combination/tissue-bad products.
医疗器械服务（Medical Device Services）
一体化的服务加速了产品从构想到商业化的转化
药明康德的服务确保了医疗器械的生产、包装和灭菌符合GMP的指导原则。另外，我们提供用于研究医疗器械的生物安全性和生物相容性的所有相关的试验方法。
测试服务（符合GLP和GMP的标准）包括：常规的设备性能和材料测试；按照FDA/ISO 10993和JMHLW（日本）进行的完整的生物相容性测试；毒理发现和安全性研究；各种用于商业生产的灭菌方法的产品验证方案；批出厂检测，原料和载体的合格性检测；受控环境的全面检测服务。
